The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis
Open accessAbstract
BACKGROUND: Disorders of mineral metabolism, including secondary hyperparathyroidism, are thought to contribute to extraskeletal (including vascular) calcification among patients with chronic kidney disease. It has been hypothesized that treatment with the calcimimetic agent cinacalcet might reduce the risk of death or nonfatal cardiovascular events in such patients. METHODS: In this clinical trial, we randomly assigned 3883 patients with moderate-to-severe secondary hyperparathyroidism (median level of intact parathyroid hormone, 693 pg per milliliter [10th to 90th percentile, 363 to 1694]) who were undergoing hemodialysis to receive either cinacalcet or placebo. All patients were eligible to receive conventional therapy, including phosphate binders, vitamin D sterols, or both. The patients were followed for up to 64 months. The primary composite end point was the time until death, myocardial infarction, hospitalization for unstable angina, heart failure, or a peripheral vascular event. The primary analysis was performed on the basis of the intention-to-treat principle. RESULTS: The median duration of study-drug exposure was 21.2 months in the cinacalcet group, versus 17.5 months in the placebo group. The primary composite end point was reached in 938 of 1948 patients (48.2%) in the cinacalcet group and 952 of 1935 patients (49.2%) in the placebo group (relative hazard in the cinacalcet group vs. the placebo group, 0.93; 95% confidence interval, 0.85 to 1.02; P=0.11). Hypocalcemia and gastrointestinal adverse events were significantly more frequent in patients receiving cinacalcet. CONCLUSIONS: In an unadjusted intention-to-treat analysis, cinacalcet did not significantly reduce the risk of death or major cardiovascular events in patients with moderate-to-severe secondary hyperparathyroidism who were undergoing dialysis. (Funded by Amgen; EVOLVE ClinicalTrials.gov number, NCT00345839.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
Block, G. A., Klassen, P. S., Lazarus, J. M., Ofsthun, N., Lowrie, E. G., & Chertow, G. M. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000133041.27682.a2 · Cited by 2,687
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
MacLeod, A. M. (2009) · Kidney International · Cited by 2,218
O'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,889
Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis
Eknoyan, G., Beck, G. J., Cheung, A. K., Daugirdas, J. T., Greene, T., Kusek, J. W., Allon, M., Bailey, J., Delmez, J. A., Depner, T. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021583 · Cited by 1,882
Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
Gutiérrez, O. M., Mannstadt, M., Isakova, T., Rauh-Hain, J. A., Tamez, H., Shah, A., Smith, K., Lee, H., Thadhani, R., Jüppner, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706130 · Cited by 1,727
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Block, G. A., Martin, K. J., de Francisco, A. L. M., Turner, S. A., Avram, M. M., Suranyi, M. G., Hercz, G., Cunningham, J., Abu-Alfa, A. K., Messa, P., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031633 · Cited by 1,139
Foley, R. N., Murray, A. M., Li, S., Herzog, C. A., McBean, A. M., Eggers, P. W., & Collins, A. J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004030203 · Cited by 972
Kalantar-Zadeh, K., Kuwae, N., Regidor, D. L., Kovesdy, C. P., Kilpatrick, R. D., Shinaberger, C. S., McAllister, C. J., Budoff, M. J., Salusky, I. B., & Kopple, J. D. (2006) · Kidney International · doi:10.1038/sj.ki.5001514 · Cited by 905
Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in Maintenance Dialysis Patients
Chiu, Y.-W., Teitelbaum, I., Misra, M., de Leon, E. M., Adzize, T., & Mehrotra, R. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00290109 · Cited by 601
Raggi, P., Chertow, G. M., Torres, P. U., Csiky, B., Naso, A., Nossuli, K., Moustafa, M., Goodman, W. G., Lopez, N., Downey, G., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq725 · Cited by 574
Cunningham, J., Danese, M., Olson, K., Klassen, P., & Chertow, G. M. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00596.x · Cited by 566
Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population
Floege, J., Kim, J., Ireland, E., Chazot, C., Drueke, T., de Francisco, A., Kronenberg, F., Marcelli, D., Passlick-Deetjen, J., Schernthaner, G., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq219 · Cited by 477
Lindberg, J. S., Culleton, B., Wong, G., Borah, M. F., Clark, R. V., Shapiro, W. B., Roger, S. D., Husserl, F. E., Klassen, P. S., Guo, M. D., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004060512 · Cited by 413
Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease
Tonelli, M., Isles, C., Curhan, G. C., Tonkin, A., Pfeffer, M. A., Shepherd, J., Sacks, F. M., Furberg, C., Cobbe, S. M., Simes, J., et al. (2004) · Circulation · doi:10.1161/01.cir.0000143892.84582.60 · Cited by 381
Melamed, M. L., Eustace, J. A., Plantinga, L., Jaar, B. G., Fink, N. E., Coresh, J., Klag, M. J., & Powe, N. R. (2006) · Kidney International · doi:10.1038/sj.ki.5001542 · Cited by 354
Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia
London, G. M., Marchais, S. J., Guérin, A. P., & Métivier, F. (2005) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000168336.67499.c0 · Cited by 258
Quarles, L. D., Sherrard, D. J., Adler, S., Rosansky, S. J., McCary, L. C., Liu, W., Turner, S. A., & Bushinsky, D. A. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000050224.03126.ad · Cited by 248
Vascular Incompetence in Dialysis Patients—Protein‐Bound Uremic Toxins and Endothelial Dysfunction
Jourde‐Chiche, N., Dou, L., Cerini, C., Dignat‐George, F., & Brunet, P. (2011) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2011.00925.x · Cited by 187
Chertow, G. M., Pupim, L. B., Block, G. A., Correa-Rotter, R., Drueke, T. B., Floege, J. D., Goodman, W. G., London, G. M., Mahaffey, K. W., Moe, S. M., et al. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04381206 · Cited by 160
Mallamaci, F., Tripepi, G. L., Cutrupi, S., Malatino, L., & Zoccali, C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00338.x · Cited by 132
Himmelfarb, J. (2009) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2009.00659.x · Cited by 120
Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications
Briet, M. B., & Burns, K. D. (2012) · Clinical Science · doi:10.1042/cs20120074 · Cited by 115
Pravastatin and cardiovascular risk in moderate chronic kidney disease
Nakamura, H., Mizuno, K., Ohashi, Y., Yoshida, T., Hirao, K., & Uchida, Y. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.031 · Cited by 87
Chronic Inflammation and Coronary Atherosclerosis in Patients with End-Stage Renal Disease
Nusair, M. B., Rajpurohit, N., & Alpert, M. (2012) · Cardiorenal Medicine · doi:10.1159/000337082 · Cited by 53
Sympathetic Activation and Baroreflex Function during Intradialytic Hypertensive Episodes
Rubinger, D., Backenroth, R., & Sapoznikov, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036943 · Cited by 52
Chertow, G. M., Correa-Rotter, R., Block, G. A., Drüeke, T. B., Floege, J., Goodman, W. G., Herzog, C. A., Kubo, Y., London, G. M., Mahaffey, K. W., et al. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr777 · Cited by 49
Anemia and Cardiovascular Risk in the Patient with Kidney Disease
Fishbane, S. (2008) · Heart Failure Clinics · doi:10.1016/j.hfc.2008.03.005 · Cited by 42
Drechsler, C., Krane, V., Grootendorst, D. C., Ritz, E., Winkler, K., März, W., Dekker, F. W., & Wanner, C. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp260 · Cited by 39
Suzuki, T., Yonemura, K., Maruyama, Y., Takahashi, T., Takita, T., Furuhashi, M., & Hishida, A. (2004) · Blood Purification · doi:10.1159/000078700 · Cited by 18
Cited by
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F., Matsushita, K., & Wen, C. P. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60595-4 · Cited by 2,213
(2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.04.001 · Cited by 1,956
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Metadata
- Authors
- The EVOLVE Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-12-27
- Volume
- 367
- Issue
- 26
- Pages
- 2482-2494
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2109064733
- Cited by
- 971
- References
- 36
- FWCI
- 63.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.